文献速递胸部肿瘤

靶向治疗联合放疗在不可手术I至III期非小细胞肺癌中的新兴作用:IASLC ART分委员会综述

Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee.
PubMed 文献 · J Thorac Oncol · 2025-05-09

本文综述了不可手术I至III期NSCLC中靶向治疗联合胸部放疗的临床证据,包括可操作驱动基因突变的发生率、联合治疗的毒性特征、最佳排序策略及正在进行的临床试验。近期报告显示,第三代酪氨酸激酶抑制剂奥希替尼在不可手术EGFR突变III期NSCLC放化疗后带来无进展生存获益。

要点

  • 不可手术I至III期NSCLC患者中,靶向治疗联合放疗的新兴证据正在积累。
  • 第三代酪氨酸激酶抑制剂奥希替尼在不可手术EGFR突变III期NSCLC放化疗后报告无进展生存获益。
  • 综述涵盖联合治疗毒性、最佳排序策略及正在进行的临床试验。

核心结论

  • 明确的生物学依据支持靶向治疗联合放疗在新辅助、同步和辅助治疗中的协同效应。
  • 先进的临床试验方法学可能促进该领域进一步研究,尤其是针对罕见基因突变,以改善患者结局。

研究设计与样本

  • 叙述性文献综述,检索PubMed、OVID(EMBASE)和ClinicalTrials.gov,以识别评估靶向治疗联合放疗在不可手术I至III期NSCLC中应用的研究。

主要发现

  • 近期报告显示,第三代酪氨酸激酶抑制剂奥希替尼在不可手术EGFR突变III期NSCLC患者放化疗后带来无进展生存获益。
  • 综述提供了可操作驱动基因突变的发生率及靶向治疗联合胸部放疗的新兴临床证据概述。
  • 综述重点介绍了联合治疗的毒性特征、最佳排序策略、正在进行的临床试验及未来展望。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision oncology has transformed the management of NSCLC by tailoring treatment to the specific genetic alterations driving oncogenesis. Targeted therapies, such as tyrosine kinase inhibitors, have been found to dramatically improve survival in patients with advanced-stage NSCLC. However, treatment options remain limited for patients with early or locally advanced stage (I-III) NSCLC harboring driver mutations, when the disease is not resectable, or the patient is unsuitable for surgery due to poor fitness or comorbidities. There is growing interest in combining targeted therapies with radiotherapy to optimize treatment outcomes for this patient group. Notably, a progression-free survival benefit has recently been reported with the third-generation tyrosine kinase inhibitor osimertinib in patients with inoperable, EGFR-mutated, stage III NSCLC after chemoradiotherapy. A narrative review of the literature was performed using PubMed, OVID (EMBASE), and ClinicalTrials.gov to identify studies evaluating the combination of targeted therapies and radiotherapy in inoperable stages I to III NSCLC. This review provides a comprehensive overview of the incidence of actionable driver alterations and emerging clinical evidence on combining targeted therapies with thoracic radiotherapy in patients with inoperable stages I to III NSCLC. The toxicity profile of combination treatments, optimal sequencing strategies, ongoing clinical trials, and future perspectives in this field are highlighted. In summary, a clear biological rationale supports the synergistic effects of combining targeted therapies with radiotherapy in the neoadjuvant, concurrent, and adjuvant settings. Advanced clinical trial methodologies may facilitate further research in this area, particularly for rare genetic alterations, to improve outcomes for these patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Bowen Jones S, Chan C, Filippi AR, et al. Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee. J Thorac Oncol. 2025. PMID: 40350081. doi:10.1016/j.jtho.2025.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。